Profile data is unavailable for this security.
About the company
Genus plc is a United Kingdom-based animal genetics company. It supplies breeding animals with desirable characteristics to farmers, enabling them to produce quality meat and milk. The Company's segments include Genus PIC, Genus ABS and Genus Research and Development. The Genus PIC segment is engaged in porcine sales business. The Genus ABS segment is engaged in bovine sales business. Its bovine genetics business sells dairy and beef bull semen and embryos from its superior cattle, which are sold to farmers to breed their cows through artificial insemination. Its porcine genetics business sells genetically superior breeding pigs and semen to farmers, so they can breed commercial pigs with desirable characteristics for pork production. It also provides technical services and advice to farmers, to maximize the performance of its breeding animals in their farms. It operates in over 24 countries on six continents, with research laboratories located in Madison, Wisconsin, United States.
- Revenue in GBP (TTM)662.40m
- Net income in GBP34.40m
- Incorporated1994
- Employees3.33k
- LocationGenus PLCMatrix House, Basing ViewBASINGSTOKE RG21 4DZUnited KingdomGBR
- Phone+44 125 634 7100
- Fax+44 125 647 7385
- Websitehttps://www.genusplc.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oxford BioMedica plc | 139.99m | -39.16m | 445.17m | 904.00 | -- | 2.17 | -- | 3.18 | -0.4149 | -0.4149 | 1.48 | 2.13 | 0.4015 | 6.39 | 3.46 | 154,855.10 | -12.95 | -4.45 | -15.77 | -5.69 | 49.42 | 53.90 | -32.26 | -8.16 | 3.40 | -3.28 | 0.3261 | -- | -1.97 | 30.08 | -305.97 | -- | 52.60 | -- |
| Ergomed PLC | 145.26m | 14.98m | 492.54m | 1.44k | 33.21 | 5.76 | 23.66 | 3.39 | 0.2921 | 0.2921 | 2.83 | 1.68 | 1.23 | -- | 5.30 | 101,087.00 | 12.73 | 8.53 | 18.60 | 12.59 | 40.72 | 41.46 | 10.31 | 7.18 | -- | 22.33 | 0.0332 | 0.00 | 22.50 | 24.99 | 18.21 | -- | 6.10 | -- |
| Puretech Health PLC | 12.55m | -40.45m | 643.86m | 111.00 | -- | 1.54 | -- | 51.32 | -0.1406 | -0.1406 | 0.0436 | 1.51 | 0.019 | -- | 2.08 | 113,032.10 | -4.50 | 5.21 | -5.58 | 6.53 | -- | -- | -237.32 | 265.77 | -- | -2.46 | 0.0789 | 0.00 | -10.18 | 43.86 | 16.85 | -- | 0.046 | -- |
| Genus plc | 662.40m | 34.40m | 1.67bn | 3.33k | 48.53 | 2.89 | 23.77 | 2.53 | 0.5242 | 0.5242 | 10.08 | 8.79 | 0.6899 | -- | 5.76 | 199,218.00 | 2.79 | 3.23 | 3.23 | 3.80 | -- | -- | 4.05 | 5.04 | 1.36 | 51.58 | 0.3106 | 67.18 | 3.33 | 5.27 | -13.53 | 4.51 | 28.18 | 6.28 |
| Worldwide Healthcare Trust PLC | -59.72m | -84.06m | 2.00bn | 0.00 | -- | 0.9167 | -- | -- | -1.28 | -1.28 | -0.9149 | 35.51 | -0.0233 | -- | -- | -- | -3.28 | 7.07 | -3.57 | 7.52 | -- | 86.92 | -- | 84.78 | -- | -- | 0.00 | 10.32 | -125.52 | -- | -129.67 | -- | -- | 3.33 |
| Indivior PLC | 761.57m | -40.17m | 2.05bn | 928.00 | -- | 35.38 | -- | 2.69 | -0.3434 | -0.3434 | 5.34 | 0.4195 | 0.545 | 1.50 | 4.65 | 820,653.40 | -2.87 | 4.76 | -5.85 | 9.11 | 83.02 | 84.52 | -5.27 | 9.42 | 0.9578 | -- | 0.7949 | 0.00 | 13.91 | -3.79 | -136.59 | -- | -32.56 | -- |
| Hikma Pharmaceuticals Plc | 2.02bn | 151.03m | 4.01bn | 8.84k | 27.33 | 2.33 | 13.10 | 1.98 | 0.6638 | 0.6638 | 8.99 | 7.79 | 0.5693 | 1.70 | 3.36 | 228,863.30 | 4.32 | 9.13 | 5.68 | 12.54 | 50.26 | 50.86 | 7.59 | 15.51 | 1.14 | 6.70 | 0.3739 | 31.08 | -1.41 | 5.39 | -55.34 | -- | 8.30 | 10.11 |
| Dechra Pharmaceuticals plc | 726.80m | 40.10m | 4.14bn | 2.04k | 101.18 | 4.91 | 31.53 | 5.69 | 0.359 | 0.359 | 6.52 | 7.39 | 0.4975 | 1.67 | 6.87 | 356,974.50 | 2.74 | 3.55 | 3.06 | 4.00 | 57.15 | 56.74 | 5.52 | 7.22 | 1.40 | 11.54 | 0.3779 | 96.35 | 12.14 | 13.67 | 4.86 | 17.39 | 48.50 | 15.93 |
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 01 Sep 2022 | 5.92m | 8.99% |
| Vanguard Advisers, Inc.as of 01 May 2023 | 3.65m | 5.55% |
| Threadneedle Asset Management Ltd.as of 08 Nov 2021 | 3.58m | 5.45% |
| Capital Research & Management Co. (World Investors)as of 01 Sep 2022 | 3.32m | 5.05% |
| Wellington Management Co. LLPas of 05 May 2023 | 3.12m | 4.75% |
| Devon Equity Management Ltd.as of 13 Sep 2022 | 2.67m | 4.07% |
| BlackRock Fund Advisorsas of 01 Sep 2022 | 2.44m | 3.70% |
| abrdn Investments Ltd.as of 23 May 2023 | 2.28m | 3.47% |
| The Vanguard Group, Inc.as of 01 Sep 2022 | 2.25m | 3.41% |
| Norges Bank Investment Managementas of 10 Nov 2020 | 1.89m | 2.87% |
